Breakthroughs come from unexpected places.
At Alector, we combine scientific rigor and deep expertise in human genetics, immunology, neuroscience, protein and nucleic acid engineering, and artificial intelligence with our Alector Brain Carrier (ABC) technology to develop therapies designed to reach the brain and make a meaningful difference for people living with devastating neurodegenerative diseases.
The resolve to confront unmet needs in neurodegenerative disease.
We imagine a different world – one where lives are not hopelessly upended by neurodegeneration. That vision drives everything we do: building a pipeline grounded in rigorous science and targeting the underlying drivers of neurodegenerative diseases, with the goal of one day preventing them altogether.
A focused pipeline powered by ABC.
Our proprietary ABC technology is designed to address one of the greatest challenges in neurodegenerative disease: delivering therapies across the blood-brain barrier and into the brain. Built to support multiple modalities – including antibodies, enzymes, and siRNA – ABC provides a versatile foundation for developing next-generation therapeutics with the potential for deeper brain penetration, improved efficacy and more convenient administration. This platform approach enables us to pursue a diverse portfolio of programs across neurodegenerative diseases.
Helping patients is our purpose.
What if diseases of aging weren’t an inevitability? What if we could slow or even halt the seemingly inescapable path toward decline associated with certain conditions? We exist to ask these bold questions, and we seek answers by advancing an understanding of diseases as we discover and develop innovative therapeutic candidates that we hope may someday make a profound impact on people’s lives.
We live a culture of courage.
We relish a challenge and bring a spirit of curiosity, empathy, and collaboration to our daily work. This mindset motivates and guides us as we forge new paths to deliver urgently needed, potentially transformative therapeutics.
